Brilinta, a new antiplatelet drug
You'll hear lots of buzz about Brilinta, a new antiplatelet drug.
Brilinta (ticagrelor) will compete with Plavix (clopidogrel) and Effient (prasugrel)...for acute coronary syndrome or after a stent.
Plavix will still lead the pack...for a while. It was the first one approved and is used the most. But it's not perfect.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote